eShowcase: PHT eSense Sensors
Tools for Clinical Trials Professionals
Wireless technology takes the worry out of inaccurate patient reported outcomes
PHT Corporation (Charlestown, MA) has created a new device that employs wireless technology to measure physiological measurements such as peak expiratory flow or blood sugar levels wirelessly, then integrates the data with an eDiary. The technology also enables subjects to send subjective data such as pain level versus activity level. With eSense, they can wear a small device to record data during the day, then return home and transmit the information to an eDiary that night. The advantage, says PHT, is that clinical trial subjects no longer have to remember scores or times, or worry about transcription errors.
The technology that makes eSense possible is a low-power wireless design that allows devices within 10 feet of each other to communicate. This also enables eSense to be integrated into tiny, wearable devices that are more convenient. Subjects simply use the device near their eDiary and the data transmits automatically, with date and time stamps for every reading.
PHT eSense Sensors
PHT Corporation, (617) 973-1600, www.phtcorp.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
